Joshua Samraj, MD
Internal Medicine · Columbus, GANPI 1215047014
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 146 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AstraZeneca at 25.8% of the total. Reporting peaked in 2019 at $1,780 and has fallen 77.5% since, to $400 in 2025. Among internal medicine clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 146 payments — averaging $35.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$601
- Pfizer$385
- Lilly USA, LLC$348
- Johnson & Johnson$346
- Bayer$326
- plus $2K from 23 others
Across 19 payments — averaging $12,390 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exact Sciences$235K
What the payments were for
- Food & beverage$5,10798%
- Education$210%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $1,339 |
| GSK | 9 | $601 |
| Pfizer | 18 | $385 |
| Lilly USA, LLC | 19 | $348 |
| Johnson & Johnson | 7 | $346 |
| Bayer | 10 | $326 |
| Novo Nordisk | 13 | $191 |
| Sanofi-aventis U.S. LLC | 3 | $170 |
| Amarin Pharma, Inc. | 4 | $162 |
| Vifor Pharma, Inc. | 2 | $130 |
| Idorsia Pharmaceuticals US Inc | 1 | $125 |
| Esperion Therapeutics, Inc. | 2 | $120 |
| Amgen(2 entities) | 2 | $118 |
| Astellas Pharma US Inc | 5 | $116 |
| Boehringer Ingelheim | 4 | $110 |
| Novartis | 6 | $101 |
| Avanir Pharmaceuticals, Inc. | 5 | $90 |
| Merck | 4 | $78 |
| AbbVie | 5 | $77 |
| Mannkind Corporation | 1 | $59 |
| Eisai Inc. | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Ossur Americas, Inc. | 1 | $21 |
| Cequr Corporation | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,187 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 45 | $54,332 |
| JardianceEmpagliflozin | 41 | $48,823 |
| EliquisApixaban | 42 | $41,136 |
| TrulicityDulaglutide | 35 | $39,173 |
| FarxigaDapagliflozin Propanediol | 31 | $33,471 |
| LinzessLinaclotide | 37 | $27,526 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $21,842 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $16,814 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $16,106 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $10,608 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $6,753 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 365 | $4,930 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 115 | $4,671 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 158 | $4,612 |
| Sucralfate | 33 | $3,897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $110 | $65,63761 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,339 | $55,31366 claims |
| Novo NordiskOzempic | $191 | $54,33245 claims |
| PfizerEliquis | $385 | $41,13642 claims |
| Lilly USA, LLCTrulicity | $348 | $39,17335 claims |
| AbbVieLinzess | $77 | $27,52637 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $601 | $26,71441 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Columbus
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.